Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism

J Bone Miner Res. 2001 Jan;16(1):189-90. doi: 10.1359/jbmr.2001.16.1.189.
No abstract available

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alkaline Phosphatase / blood
  • Bone Density / drug effects
  • Calcium / blood
  • Calcium / urine
  • Creatinine / urine
  • Female
  • Femur Neck / drug effects
  • Femur Neck / metabolism
  • Humans
  • Hyperparathyroidism / blood
  • Hyperparathyroidism / complications*
  • Lumbar Vertebrae / drug effects
  • Lumbar Vertebrae / metabolism
  • Middle Aged
  • Osteoporosis, Postmenopausal / blood
  • Osteoporosis, Postmenopausal / complications*
  • Osteoporosis, Postmenopausal / drug therapy*
  • Osteoporosis, Postmenopausal / metabolism
  • Parathyroid Hormone / blood
  • Phosphates / blood
  • Raloxifene Hydrochloride / administration & dosage
  • Raloxifene Hydrochloride / pharmacology
  • Raloxifene Hydrochloride / therapeutic use*
  • Selective Estrogen Receptor Modulators / administration & dosage
  • Selective Estrogen Receptor Modulators / pharmacology
  • Selective Estrogen Receptor Modulators / therapeutic use
  • Time Factors

Substances

  • Parathyroid Hormone
  • Phosphates
  • Selective Estrogen Receptor Modulators
  • Raloxifene Hydrochloride
  • Creatinine
  • Alkaline Phosphatase
  • Calcium